Breaking News Instant updates and real-time market news.

INCY

Incyte

$94.78

-0.91 (-0.95%)

, MRK

Merck

$62.66

-0.14 (-0.22%)

04:54
10/07/16
10/07
04:54
10/07/16
04:54

Incyte announces updated data from Phase I portion of ECHO-202 trial

Incyte (INCY) announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with pembrolizumab, Merck's (MRK) anti-PD-1 therapy, have been published as a poster at the European Society for Medical Oncology Annual Congress 2016 in Copenhagen, Denmark. Further to the previously published abstract, today's updated data show that among patients with treatment-naive advanced melanoma, the combination of epacadostat plus pembrolizumab resulted in progression-free survival, or PFS, rates of 74 percent and 57 percent at 6 months and 12 months, respectively. Median PFS has not been reached. The updated data also show an increase in the complete response, or CR, rate to 26 percent. The objective response rate, or ORR, and disease control rate, or DCR, remained consistent with the previously published abstract data, at 58 percent and 74 percent, respectively. All responses are confirmed and ongoing. Epacadostat in combination with pembrolizumab was well tolerated in the Phase 1 population.

INCY

Incyte

$94.78

-0.91 (-0.95%)

MRK

Merck

$62.66

-0.14 (-0.22%)

  • 07

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$94.78

-0.91 (-0.95%)

09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
MRK Merck
$62.66

-0.14 (-0.22%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

TODAY'S FREE FLY STORIES

AMPH

Amphastar

$16.27

0.17 (1.06%)

, AVDL

Avadel Pharmaceuticals

$9.45

-0.16 (-1.66%)

18:59
09/25/17
09/25
18:59
09/25/17
18:59
Hot Stocks
Amphastar announces FDA approval of Neostigmine Methylsulfate Injection, USP »

Amphastar (AMPH)…

AMPH

Amphastar

$16.27

0.17 (1.06%)

AVDL

Avadel Pharmaceuticals

$9.45

-0.16 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 04

    Oct

  • 05

    Oct

ACN

Accenture

$138.16

0.26 (0.19%)

18:58
09/25/17
09/25
18:58
09/25/17
18:58
Hot Stocks
Accenture chief marketing & communications officer Taylor to retire Aug 31, 2018 »

Accenture announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

SPR

Spirit AeroSystems

$78.07

-0.38 (-0.48%)

, BA

Boeing

$254.32

-2.13 (-0.83%)

18:31
09/25/17
09/25
18:31
09/25/17
18:31
Hot Stocks
Spirit AeroSystems finalizes agreement with Boeing »

Spirit AeroSystems (SPR)…

SPR

Spirit AeroSystems

$78.07

-0.38 (-0.48%)

BA

Boeing

$254.32

-2.13 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:17
09/25/17
09/25
18:17
09/25/17
18:17
Hot Stocks
Senator Collins opposes Graham-Cassidy ACA repeal bill »

U.S. Senator Susan…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

18:15
09/25/17
09/25
18:15
09/25/17
18:15
General news
Breaking General news story  »

Minneapolis Federal…

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

18:13
09/25/17
09/25
18:13
09/25/17
18:13
Downgrade
Cardtronics rating change  »

Cardtronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$7.80

-0.5 (-6.02%)

18:10
09/25/17
09/25
18:10
09/25/17
18:10
Recommendations
Invuity analyst commentary  »

Invuity's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:05
09/25/17
09/25
18:05
09/25/17
18:05
Hot Stocks
CBO: Graham-Cassidy ACA repeal bill to reduce number of insured by 'millions' »

The Congressional Budget…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

GPC

Genuine Parts

$93.22

5.24 (5.96%)

18:04
09/25/17
09/25
18:04
09/25/17
18:04
Recommendations
Genuine Parts analyst commentary at RBC Capital »

Genuine Parts acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

AA

Alcoa

$45.29

-0.09 (-0.20%)

, FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Recommendations
Alcoa, Freeport McMoRan, Teck Resources, Newmont Mining, Warrior Met Coal, Cleveland-Cliffs analyst commentary at Morgan Stanley »

Morgan Stanley raising…

AA

Alcoa

$45.29

-0.09 (-0.20%)

FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

TECK

Teck Resources

$21.24

-0.72 (-3.28%)

NEM

Newmont Mining

$38.63

0.74 (1.95%)

HCC

Warrior Met Coal

$24.11

0.76 (3.25%)

CLF

Cleveland-Cliffs

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 20

    Oct

  • 26

    Oct

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Conference/Events
Federal Reserve Bank of Minneapolis President participates in a discussion »

Minneapolis Federal…

FTK

Flotek

$5.40

0.04 (0.75%)

17:49
09/25/17
09/25
17:49
09/25/17
17:49
Earnings
Flotek cuts Q3 revenue view by $5M, consensus $90.9M »

Flotek announced impacts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 14

    Nov

  • 16

    May

NBLX

Noble Midstream

$54.11

3.75 (7.45%)

17:44
09/25/17
09/25
17:44
09/25/17
17:44
Recommendations
Noble Midstream analyst commentary at MUFG »

Noble Midstream guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 31

    Oct

FB

Facebook

$162.87

-7.67 (-4.50%)

17:38
09/25/17
09/25
17:38
09/25/17
17:38
Periodicals
Russia looked to 'exploit' divisions in U.S. populace with Facebook ads, WP says »

The collection of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

, SNX

Synnex

$116.50

0.4 (0.34%)

17:35
09/25/17
09/25
17:35
09/25/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

SNX

Synnex

$116.50

0.4 (0.34%)

RHT

Red Hat

$105.76

-0.54 (-0.51%)

ACTA

Actua

$12.25

-0.1 (-0.81%)

PRQR

ProQR Therapeutics

$6.45

0.25 (4.03%)

GNCA

Genocea

$5.33

0.04 (0.76%)

KDMN

Kadmon

$3.79

0.27 (7.67%)

QEP

QEP Resources

$8.88

0.51 (6.09%)

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

CSGP

CoStar Group

$279.20

-1.62 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 16

    Oct

  • 17

    Oct

  • 03

    Nov

GKOS

Glaukos

$31.26

-0.93 (-2.89%)

17:30
09/25/17
09/25
17:30
09/25/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Glaukos »

James E. Flynn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

17:28
09/25/17
09/25
17:28
09/25/17
17:28
Hot Stocks
Bioptix changes state of incorporation to Nevada from Colorado »

Bioptix said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$254.32

-2.13 (-0.83%)

17:26
09/25/17
09/25
17:26
09/25/17
17:26
Hot Stocks
Boeing and Qatar Airways announce order valued at $2.16B »

Boeing and Qatar Airways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CLXT

Calyxt

$26.54

0.82 (3.19%)

17:25
09/25/17
09/25
17:25
09/25/17
17:25
Hot Stocks
Calyxt: Herbicide-tolerant wheat, oil composition canola move to Phase 1 »

Calyxt announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MNK

Mallinckrodt

$35.25

0.42 (1.21%)

17:03
09/25/17
09/25
17:03
09/25/17
17:03
Earnings
Mallinckrodt sees InfaCare acquisition 15c-20c dilutive to FY17 adjusted EPS »

Mallinckrodt announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

FTI

TechnipFMC

$27.02

0.19 (0.71%)

17:02
09/25/17
09/25
17:02
09/25/17
17:02
Hot Stocks
TechnipFMC implements share repurchase of up to $500M »

TechnipFMC announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GNCA

Genocea

$5.33

0.04 (0.76%)

17:01
09/25/17
09/25
17:01
09/25/17
17:01
Hot Stocks
Breaking Hot Stocks news story on Genocea 

Genocea trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

16:53
09/25/17
09/25
16:53
09/25/17
16:53
Syndicate
TherapeuticsMD files to sell 12.4M shares of common stock »

J.P. Morgan is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Nov

LLL

L3 Technologies

$189.32

0.04 (0.02%)

16:52
09/25/17
09/25
16:52
09/25/17
16:52
Hot Stocks
L3 Technologies files protest with GAO related to Fort Rucker contract »

L3 Technologies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRI

Apricus Biosciences

$1.73

0.05 (2.98%)

16:50
09/25/17
09/25
16:50
09/25/17
16:50
Syndicate
Apricus Biosciences requests withdrawal of registration statement »

The company confirms that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.